美国生物制药公司Sarepta Therapeutics(SRPT)11月7日盘前大涨近4%,股价上涨至132.97美元。公司此前公布的第三季度财报数据显示,营收4.672亿美元,高于华尔街分析师此前的4.093亿美元预期,主要得益于旗舰产品Elevidys销售表现亮眼。
Elevidys是SRPT公司主要针对治疗罕见疾病杜氏肌营养不良症推出的基因疗法药物,第三季度产品净收入达1.81亿美元。公司称,该药品能有效改善该疾病 young患者的生存质量。杜氏肌营养不良症会导致骨骼及心肌变弱无力,患者病情随时间推移会迅速恶化。
与此同时,SRPT也宣布决定停止开发SRP-5051药物治疗方案,因为少数患者使用后出现了持续性低镁血症反应。不过该决定影响有限,投资人目前更看重公司在商业化上的营收表现,股价在过去一个月上涨约32%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.